Maxime Castan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maxime Castan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alain Viallon
Emergency and Intensive Care Department, Hôpital de Bellevue, Saint-Etienne, France
1 shared publication David M. Smadja
Univ Paris, Innovat Therapies Haemostasis, INSERM, F-75006 Paris, France
1 shared publicationDominique Page
CHU St Etienne, Serv Medecine Inten & Reanimat, F-42055 St Etienne, France
1 shared publicationGuillaume Thiéry
CHU St Etienne, Serv Medecine Inten & Reanimat, F-42055 St Etienne, France
1 shared publication- Géraldine Poenou
Therapeutic and Vascular Medicine Department, Universitary Medical Center of Saint Etienne, Saint-Étienne, France.
1 shared publication Laurent Bertoletti
CHU St Etienne, Serv Medecine Vasc & Therapeut, F-42055 St Etienne, France
1 shared publication
Latest Publications
- Open Access
Cardiac Biomarkers in Patients with Acute Pulmonary Embolism
Pulmonary embolism is a frequent and potentially fatal disease. The major challenge of initial management lies in prognostic stratification. Since 2014, the European recommendations on the diagnosis and management of acute pulmonary embolism are based on assessing the risk stratification regarding hemodynamic status first, then on a combined risk assessment model using a clinical score, an imaging evaluation of right heart size and the concentration of a serum cardiac biomarker. Usual biomarkers cover cardiac ischemia (troponin and derivates) and dilatation (BNP and derivates). The aim of this review is to offer a practical update on the role of the Troponins and BNPs families of biomarkers and the prognosis of pulmonary embolism, and furthermore, to provide a brief overview of their place in current management.
Open AccessCardiac Biomarkers in Patients with Acute Pulmonary Embolism
Pulmonary embolism is a frequent and potentially fatal disease. The major challenge of initial management lies in prognostic stratification. Since 2014, the European recommendations on the diagnosis and management of acute pulmonary embolism are based on assessing the risk stratification regarding hemodynamic status first, then on a combined risk assessment model using a clinical score, an imaging evaluation of right heart size and the concentration of a serum cardiac biomarker. Usual biomarkers cover cardiac ischemia (troponin and derivates) and dilatation (BNP and derivates). The aim of this review is to offer a practical update on the role of the Troponins and BNPs families of biomarkers and the prognosis of pulmonary embolism, and furthermore, to provide a brief overview of their place in current management.